Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | The Journal of Liquid Biopsy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950195423000784 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846160175651618816 |
|---|---|
| author | I. Arévalo L. García I. Lodewijk E. Montesinos O. Alberquilla R. Sánchez D. Castellanos J. Paramio M. Dueñas C. Rubio |
| author_facet | I. Arévalo L. García I. Lodewijk E. Montesinos O. Alberquilla R. Sánchez D. Castellanos J. Paramio M. Dueñas C. Rubio |
| author_sort | I. Arévalo |
| collection | DOAJ |
| format | Article |
| id | doaj-art-1fbe27f3c09a4266adeba2fa0db6eb7b |
| institution | Kabale University |
| issn | 2950-1954 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Journal of Liquid Biopsy |
| spelling | doaj-art-1fbe27f3c09a4266adeba2fa0db6eb7b2024-11-22T07:41:15ZengElsevierThe Journal of Liquid Biopsy2950-19542023-11-011100078Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma MonitoringI. Arévalo0L. García1I. Lodewijk2E. Montesinos3O. Alberquilla4R. Sánchez5D. Castellanos6J. Paramio7M. Dueñas8C. Rubio9Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainMolecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainMolecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainDivision of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain; Advanced Therapy Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, SpainDivision of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain; Advanced Therapy Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Molecular Oncology Unit. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; Cellular and Molecular Oncology Genitourinary Tumor Group. Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, Spainhttp://www.sciencedirect.com/science/article/pii/S2950195423000784 |
| spellingShingle | I. Arévalo L. García I. Lodewijk E. Montesinos O. Alberquilla R. Sánchez D. Castellanos J. Paramio M. Dueñas C. Rubio Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring The Journal of Liquid Biopsy |
| title | Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring |
| title_full | Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring |
| title_fullStr | Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring |
| title_full_unstemmed | Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring |
| title_short | Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring |
| title_sort | optimization of ctcs and thcs isolation from human blood based on genesis technology as a strategy of urothelial carcinoma monitoring |
| url | http://www.sciencedirect.com/science/article/pii/S2950195423000784 |
| work_keys_str_mv | AT iarevalo optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT lgarcia optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT ilodewijk optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT emontesinos optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT oalberquilla optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT rsanchez optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT dcastellanos optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT jparamio optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT mduenas optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring AT crubio optimizationofctcsandthcsisolationfromhumanbloodbasedongenesistechnologyasastrategyofurothelialcarcinomamonitoring |